prosonix

Médias

Prosonix and Mylan Enter Into Global Licensing Agreement for Generic Versions of Inhaled Respiratory Products Flixotide® and Flovent®

Médias

Prosonix Reports Positive Top-line Results from its Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Médias

Prosonix Enters Collaboration With Imperial College London to Accelerate Development of Engineered Combination Respiratory Medicines (Multi-component Particles™, MCPs™)